In conclusion, Oncotype DX testing has led to a clinically meaningful 58% reduction in chemotherapy administration in Irish women with ER-positive, HER2-negative breast cancer with 1–3 positive lymph nodes which has resulted in substantial cost savings for the exchequer. This evidence concerns the gene ERBB2 and breast carcinoma.